BOTHELL, Wash., Jan. 20 /PRNewswire-FirstCall/ -- Lumera Corporation (Nasdaq: LMRA), an emerging leader in nanotechnology solutions, named Jim Richey as Senior Advisor, Business Development and named Dr. Charles T. Campbell to its scientific advisory board. "The addition of Jim Richey and Dr. Charles Campbell significantly enables our ability to bring new, revolutionary products to market," said Tom Mino, chief executive officer. "We are committed to building a strong, talented and vertically integrated organization to successfully serve biotechnology and pharmaceutical customers throughout the world." Richey comes to Lumera with more than 25 years of experience in sales and marketing operations in the United States, Europe and Japan. He has held senior executive positions in numerous rapid growth biotechnology success stories including LJL BioSystems (acquired by Molecular Devices), PerSeptive BioSystems (acquired by Applied Biosystems, now Applera), Pharmacia Biosensor (now BIAcore International), and Pharmacia Biotech (acquired by Amersham and recently by General Electric, today GE Healthcare). "As we receive orders for our first proteomics products, Jim's breadth of experience and history of achievement will undoubtedly allow him to make an immediate impact on the success of our company," said Tom Mino, chief executive officer. Dr. Campbell currently holds The West Endowed Professorship of Chemistry at the University of Washington, and is co-director of the University of Washington/Pacific Northwest National Laboratory Joint Institute for Nanotechnology. He is currently Editor-in-Chief of the journal Surface Science and has served on the editorial boards of the Journals of Chemical Physics and of Cataysis. During the course of his distinguished career he has received numerous awards and recognitions. "Dr. Campbell brings a uniquely integrated knowledge of nanoelectronics, surface chemistry and biodetection techniques," says Tom Mino, Lumera chief executive officer. "We believe Dr. Campbell will have a meaningful impact as we work toward commercialization of key Lumera technologies." About Lumera Lumera is an emerging leader in the field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, RF and specialty coating applications. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com/. Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including in its registrations statement on Form S-1, dated July 22, 2004 and its Quarterly Reports on Form 10-Q.
SOURCE Lumera Corporation